Biomarker Partnering Terms and Agreements

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Biomarker Partnering Terms and Agreements

http://www.reportbuyer.com/pharma_healthcare/biotechnology/biomarkers/biomarker_partnering_terms_agreements.html

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 700 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2009. Deals are listed by headline value, signed by big pharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2009. The chapter is organized by specific biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

Trends in biomarker dealmaking in the biopharma industry since 2009
Analysis of biomarker deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life biomarker deals
Access to several biomarker contract documents
The leading biomarker deals by value since 2009
Most active biomarker dealmakers since 2009
The leading biomarker partnering resources

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 biomarker deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise biomarker rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Biomarker Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of biomarker deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of over 700 biomarker agreements with numerous real life case studies
Comprehensive access to over 50 actual biomarker contracts entered into by the world's biopharma companies
Detailed access to actual biomarker contracts enter into by the leading fifty big pharma companies
Insight into the terms included in a biomarker agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
TABLE OF CONTENTS

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Big pharma biomarker dealmaking activity
2.4. Most active biomarker dealmakers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7. Biomarker partnering by stage of development
2.8 Average deal terms for biomarkers
2.8.1 Biomarker headline values
2.8.2 Biomarker upfront payments
2.8.3 Biomarker milestone payments
2.8.4 Biomarker royalty rates
2.9. The anatomy of biomarker partnering
2.9. The anatomy of a biomarker deal
2.9.a. Case study 1: Kinemed, GlaxoSmithKline- June 2012
2.9.b. Case study 2: Roche, Rules-based Medicine, Psynova Neurotech- December 2009

Chapter 3 – Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving big pharma

Chapter 4 – Big pharma biomarker deals

4.1. Introduction
4.2. How to use big pharma biomarker partnering deals
4.3. Big pharma biomarker partnering company profiles
Abbott
Amgen
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
GlaxoSmithKline

Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva

Chapter 5 – Biomarker contracts dealmaking directory

5.1. Introduction
5.2. By Company A-Z
Abbott Laboratories
Adamis Pharmaceuticals
ADMA Biologics
Altair Nanotechnologies

Amarantus BioSciences
ARCA Biopharma
Arno Therapeutics
Arrayit 139
Arrayit Diagnostics
Avalon Pharmaceuticals
BG Medicine
Biogen Idec
Biotage
Caliper Life Sciences
Celera
Clinical Data
Columbia University
DeCODE Genetics
DiagnoCure
Enterome Bioscience
Galmed Pharmaceuticals
Gen-Probe
Genzyme
Genzyme Genetics
GlaxoSmithKline
Guided Therapeutics
Health Discovery
Intrexon
Inverness Medical Innovations
Invivis Pharmaceuticals

KineMed
Konica Minolta
Laboratory Corporation of America
Merck and Co
Novartis
Perugia University
Power3 Medical Products
Psynova Neurotech
Quest Diagnostics
Regulus Therapeutics
Response Genetics
Roche
Rules-Based Medicine
Sanofi
Skyline Diagnostics
The Regents of the University of California
Transgenomic
TrovaGene
University of Cambridge
University of Cincinnati
US Army
Wayne State University
Zora Biosciences
5.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing

Co-development
Collaborative R&D
Contract service
Development
Distribution
Equity purchase
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Supply
5.4. By therapy area
Cardiovascular
Central Nervous System
Genetic disorders
Metabolic
Musculoskeletal
Oncology
Respiratory

Chapter 6 – Biomarker dealmaking by technology type

6.1. Introduction
6.2. Deals by biomarker type
Biomarkers

Chapter 7 – Biomarker partnering resource center

7.1. Online biomarker partnering
7.2. Biomarker partnering events
7.3. Further reading on biomarker dealmaking

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports

TABLE OF FIGURES

Figure 1: Biomarker partnering since 2009
Figure 2: Big pharma – top 50 – biomarker deals 2009 to 2014
Figure 3: Big pharma biomarker deal frequency – 2009 to 2014
Figure 4: Active biomarker dealmaking activity– 2009 to 2014
Figure 5: Biomarker partnering by deal type since 2009
Figure 6: Biomarker partnering by disease type since 2009
Figure 7: Biomarker partnering by oncology target since 2009
Figure 8: Biomarker partnering by deal type since 2009
Figure 9: Biomarker deals with a headline value
Figure 10: Biomarker deal headline value distribution, US$million – 2009-2014– Discovery stage
Figure 11: Biomarker deal headline value distribution, US$million – 2009-2014 – preclinical stage
Figure 12: Biomarker deal headline value distribution, US$million – 2009-2014– phase I stage
Figure 13: Biomarker deal headline value distribution, US$million – 2009-2014– phase II stage
Figure 14: Biomarker deal headline value distribution, US$million – 2009-2014– phase III stage
Figure 15: Biomarker deal headline value distribution, US$million – 2009-2014– regulatory stage
Figure 16: Biomarker deal headline value distribution, US$million – 2009-2014– marketed stage
Figure 17: Summary median headline value by stage of development, 2009-2014

Figure 18: Biomarker deals with an upfront value
Figure 19: Biomarker deal upfront value distribution, US$million – 2009-2014– discovery stage
Figure 20: Biomarker deal upfront value distribution, US$million – 2009-2014– preclinical stage
Figure 21: Biomarker deal upfront value distribution, US$million – 2009-2014– phase I stage
Figure 22: Biomarker deal upfront value distribution, US$million – 2009-2014– phase II stage
Figure 23: Biomarker deal upfront value distribution, US$million – 2009-2014– phase III stage
Figure 24: Biomarker deal upfront value distribution, US$million – 2009-2014– regulatory stage
Figure 25: Biomarker deal upfront value distribution, US$million – 2009-2014– marketed stage
Figure 26: Summary median headline value by stage of development, 2009-2014
Figure 27: Biomarker deals with a milestone value
Figure 28: Biomarker deal milestone value distribution, US$million – 2009-2014– discovery stage
Figure 29: Biomarker deal milestone value distribution, US$million – 2009-2014– preclinical stage
Figure 30: Biomarker deal milestone value distribution, US$million – 2009-2014– phase I stage
Figure 31: Biomarker deal milestone value distribution, US$million – 2009-2014– phase II stage
Figure 32: Biomarker deal milestone value distribution, US$million – 2009-2014– phase III stage
Figure 33: Biomarker deal milestone value distribution, US$million – 2009-2014– regulatory stage
Figure 34: Biomarker deal milestone value distribution, US$million – 2009-2014– marketed stage
Figure 35: Biomarker deals with a royalty rate value
Figure 36: Biomarker deal royalty rate value distribution, US$million – 2009-2014– discovery stage
Figure 37: Biomarker deal royalty rate value distribution, US$million – 2009-2014– preclinical stage
Figure 38: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase I stage
Figure 39: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase II stage
Figure 40: Biomarker deal royalty rate value distribution, US$million – 2009-2014– phase III stage
Figure 41: Biomarker deal royalty rate value distribution, US$million – 2009-2014– regulatory stage
Figure 42: Biomarker deal royalty rate value distribution, US$million – 2009-2014– marketed stage
Figure 43: Summary median headline value by stage of development, 2009-2014
Figure 44: Components of the typical biomarker deal structure
Figure 44: Top biomarker deals by value since 2009
Figure 45: Top biomarker deals signed by big pharma value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Read the full report:
Biomarker Partnering Terms and Agreements

http://www.reportbuyer.com/pharma_healthcare/biotechnology/biomarkers/biomarker_partnering_terms_agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer